https://www.prnewswire.co.uk/news-releases/epivax-signs-first-commercial-license-for-tregitope-technology-620390943.html
EpiVax Signs First Commercial License for Tregitope Technology
/PRNewswire/ -- Providence-based biotechnology company EpiVax, Inc. ("EpiVax") has licensed its novel immune-modulating technology to an undisclosed global...
commercial licenseepivaxsignsfirsttregitope
https://www.prnewswire.com/news-releases/epivax-strengthens-technology-leadership-amid-immunoinformatics-advancements-302387204.html
EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements
/PRNewswire/ -- EpiVax, Inc. proudly announces the appointment of Guilhem Richard as Chief Technology Officer. Dr. Richard joined EpiVax's immunoinformatics...
technology leadershipepivaxamidimmunoinformaticsadvancements
https://theorg.com/org/epivax-inc/teams/office-administration
EpiVax, Inc. - Office Administration | The Org
The Office Administration team at EpiVax, Inc.
office administrationepivaxinc
https://www.biospace.com/epivax-licenses-ispri-toolkit-to-eisai-for-preclinical-in-silico-immunogenicity-screening
EpiVax Licenses ISPRI Toolkit to Eisai for Preclinical in silico Immunogenicity Screening - BioSpace
Jul 18, 2024 - EpiVax, Inc. ("EpiVax"), an internationally recognized leader in the field of immunogenicity, today announced that Eisai Co. Ltd. ("Eisai") has licensed...